⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789015 | 0.77 | — | — | |
| SCHEMBL4042478 | 0.73 | — | — | |
| SCHEMBL15332553 | 0.68 | — | — | |
| SCHEMBL10414189 | 0.67 | TSHR (0.48) | — | |
| SCHEMBL1951265 | 0.67 | — | — | |
| SCHEMBL57048 | 0.67 | — | — | |
| SCHEMBL1951911 | 0.67 | — | — | |
| SCHEMBL269360 | 0.65 | — | — | |
| SCHEMBL1483243 | 0.63 | — | — | |
| SCHEMBL570696 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762037-A1 | RELEASABLE ANTIBODY CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2021-01-13 | — | — | EP | claimed |
| WO-2019171358-A1 | RELEASABLE ANTIBODY CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2019-09-12 | — | — | WO | claimed |
| WO-2018163131-A1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2018-09-13 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-20240181017-A1 | RELEASABLE GLP-1 CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2024-06-06 | — | — | US | disclosed |
| US-11957735-B2 | Releasable GLP-1 conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2024-04-16 | — | — | US | disclosed |
| US-20240075150-A1 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | ASCENDIS PHARMA A/S (DK) | 2024-03-07 | — | — | US | disclosed |
| EP-3762037-B1 | RELEASABLE ANTIBODY CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-12-27 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20130281455-A1 | Phenylpyri(mi)dinylazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |